Royal Bank Of Canada Inhibrx, Inc. Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$32.76 - $39.56 $480,556 - $580,305	-14,669 Reduced 91.72%	1,324 $46,000
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $156,774 - $410,856	10,812 Added 208.69%	15,993 $607,000
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $28,680 - $47,910	1,821 Added 54.2%	5,181 $95,000
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $19,249 - $31,575	1,135 Added 51.01%	3,360 $87,000
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $53,486 - $78,678	-2,899 Reduced 56.58%	2,225 $41,000
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $88,469 - $146,118	4,384 Added 592.43%	5,124 $126,000
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $2,211 - $4,723	191 Added 34.79%	740 $13,000
Q2 2022 Aug 15, 2022	SELL	$8.52 - $25.26 $13,214 - $39,178	-1,551 Reduced 73.86%	549 $6,000
Q1 2022 May 16, 2022	SELL	$19.89 - $43.18 $80,614 - $175,008	-4,053 Reduced 65.87%	2,100 $47,000
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $84,155 - $144,778	3,146 Added 104.62%	6,153 $269,000
Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $17,399 - $26,126	691 Added 29.84%	3,007 $100,000
Q2 2021 Aug 16, 2021	BUY	$14.69 - $27.52 $34,022 - $63,736	2,316 New	2,316 $65,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.